References

1. Kawasaki T (1967) Acute febrile mucocutaneous lymph node syndrome in young children with unique digital desquamation. Allergy. 16: 178-222 [Google Scholar]
2. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, et al. (2006) NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8: 691-728 [CrossRef] [Google Scholar] [PubMed]
3. Sies H (1985) Oxidative stress: inductor remarks. In: Sies H (ed) Oxidative stress. Academic Press, London 1-8
4. Sies H (2000) What is oxidative stress? In: Kency JF Jr. (ed) Oxidative stress and vascular disease. Kluwer Academic Publishers 1-8
5. Phan SH, Gannon DE, Varani J, Ryan US, Ward PA (1989) Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils. Am J Pathol 134: 1201-1211 [Google Scholar] [PubMed]
6. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, et al. (1988) Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 48: 247-251 [CrossRef] [Google Scholar] [PubMed]
7. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, et al. (1992) Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-alpha and interleukin 6 in serum. Eur J Pediatr 151: 44-47 [CrossRef] [Google Scholar] [PubMed]
8. Lin CY, Lin CC, Hwang B, Chiang B (1992) Serial changes of serum interleukin-6, interleukin-8, and tumour necrosis factor alpha among patients with Kawasaki disease. J Pediatr 21: 924-926 [CrossRef] [Google Scholar] [PubMed]
9. Inamo Y, Harada K, Okuni M, Kimoto K, Takeuchi S, et al. (1987) Immunoreactive polymorphonuclear leukocyte elastase in complex with alpha 1-antitrypsin in Kawasaki disease. Acta Paediatr Jpn 29: 202-205 [CrossRef] [Google Scholar] [PubMed]
10. Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, et al. (1996) Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75: 77-785 [Google Scholar] [PubMed]
11. Yahata T, Suzuki C, Hamaoka A, Fujii M, Hamaoka K (2011) Dynamics of reactive oxygen metabolites and biological antioxidant potential in the acute stage of Kawasaki disease. Circ J 75: 2453-2459 [CrossRef] [Google Scholar] [PubMed]
12. JCS Joint Working Group (2010) Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)--digest version. Circ J 74: 1989-2020 [CrossRef] [Google Scholar] [PubMed]
13. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, et al. RAISE study group investigators (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. Lancet 28: 1613-1620 [CrossRef] [Google Scholar] [PubMed]
14. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31: 808- 810. [Google Scholar] [PubMed]
15. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, et al. (2005) Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146: 662-667 [CrossRef] [Google Scholar] [PubMed]
16. Sugimura T, Kato H, Inoue O, Fukuda T, Sato N, et al. (1994) Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 89: 258- 265 [CrossRef] [Google Scholar] [PubMed]
17. Niboshi A, Hamaoka K, Sakata K, Yamaguchi N (2008) Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 167: 189-196 [CrossRef] [Google Scholar] [PubMed]
18. Takahashi K, Oharaseki T, Naoe S (2001) Pathological study of postcoronary arteritis in adolescents and young adults: with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 22: 138-142 [CrossRef] [Google Scholar] [PubMed]
19. Ross R (1999) Atherosclerosis--an inflammatory disease. N Engl J Med 340: 115-126 [CrossRef] [Google Scholar] [PubMed]
20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924 [CrossRef] [Google Scholar] [PubMed]
21. Liu Y, Onouchi Z, Sakata K, Ikuta K (1996) An experimental study on the role of smooth muscle cells in the pathogenesis of atherosclerosis of the coronary arteritis. J Japan Pediatr Soc 100: 1453-1458
22. Silva BR, Pernomian L, Bendhack LM (2012) Contribution of oxidative stress to endothelial dysfunction in hypertension. Front Physiol 3: 441 [CrossRef] [Google Scholar] [PubMed]
23. Stephens JW, Khanolkar MP, Bain SC (2009) The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 202: 321-329 [CrossRef] [Google Scholar] [PubMed]
24. Araujo FB, Barbosa DS, Hsin CY, Maranhão RC, Abdalla DS (1995) Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis 117: 61-71 [CrossRef] [Google Scholar] [PubMed]
25. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761 [CrossRef] [Google Scholar] [PubMed]
26. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, et al. (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332: 1198-1203 [CrossRef] [Google Scholar] [PubMed]
27. Ferrières J (2004) The French paradox: lessons for other countries. Heart 90: 107-111 [CrossRef] [Google Scholar] [PubMed]
28. Praticò D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA (1998) Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4: 1189-1192 [CrossRef] [Google Scholar] [PubMed]
29. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297: 842-857 [CrossRef] [Google Scholar] [PubMed]
30. Baillie JK, Thompson AA, Irving JB, Bates MG, Sutherland AI, et al. (2009) Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM 102: 341- 348 [CrossRef] [Google Scholar] [PubMed]